source
- Viatris to acquire Pacira BioSciences for $1.65 billion, expanding its non‑opioid pain portfolioViatris, a maker of generic and branded medicines, announced a cash purchase of commercial‑stage Pacira BioSciences for $1.65 billion. The deal adds Pacira’s non‑opioid pain treatments to Viatris’…
- White House seeks data on U.S. manufacturing of 86 essential medicinesThe White House Office of Management and Budget has launched a review of domestic production for a list of 86 medicines deemed essential. The request asks manufacturers to provide information on w…